Press release
CytomX Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
- Advancing wholly owned, next-generation conditionally activated therapeuticsCX-2051 (EpCAM-directed ADC) and CX-801 (Interferon alpha-2b), with INDs
About this update from Cytomx Therapeutics, Inc.
[{"type":"text","content":"- Advancing wholly owned, next-generation conditionally activated therapeuticsCX-2051 (EpCAM-directed ADC) and CX-801 (Interferon alpha-2b), with INDs anticipated in 2023 - - CX-904, Company’s first clinical stage Probody T-cell bispecific (EFGRxCD3), continues to advance in Phase 1 dose escalation - - Continued progress with Phase 2 collaborator programs CX-2029 (AbbVie, Phase 2) and BMS-986249 (Bristol Myers Squibb, Phase 2) - SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today reported third quarter 2022 financial results and provided a business update. “CytomX’s progress in the third quarter highlights the potential of our pipeline as well as the breadth and versatility of the Probody® platform. CX-2051 and CX-801 are wholly owned, next generation therapeutic candidates that build on our deep experience with conditional activation,” said Sean McCarthy, D.Phil., chief executive officer and chairman at CytomX Therapeutics. “We also continued to make progress in our collaborator programs, including CX-904, our first T-cell engager in the clinic, and BMS-986249, for which Bristol Myers Squibb presented updated Phase 1 safety and efficacy data at ESMO 2022.” Third Quarter Business Highlights and Recent Developments CX-2051, EpCAM-directed Antibody Drug Conjugate (ADC), unveiled at World ADC in San Diego – CX-2051 is a wholly-owned, conditionally activated ADC directed toward the epithelial cell adhesion molecule (EpCAM), with potential applicability across multiple EpCAM-expressing cancers. CX-2051 is tailored to optimize the therapeutic index for systemic treatment of EpCAM-expressing cancers, an opportunity that, to date, has not been realized due to dose-limiting toxicities. CytomX’s strategy with CX-2051 is to match target expression and sensitivity to the camptothecin payload with prioritized indications. CX-2051 data presented at World ADC demonstrated strong preclinical activity and a favorable predicted therapeutic index. CytomX anticipates submitting an IND for CX-2051 in the second half of 2023. CX-801, Interferon (IFN) alpha-2b, preclinical data at SITC Annual Meeting – CX-801 is a wholly-owned IFN alpha-2b Probody therapeutic that in preclinical studies has demonstrated a wide therapeutic ...